Pfizer Swallows the Medicine

As it sheds 10,000 workers, the pharmaceutical giant under CEO Jeffrey Kindler also hopes to sharpen operations and wean itself from blockbusters

With its dispatch of 10,000 jobs and a handful of research and manufacturing operations, troubled pharmaceutical giant Pfizer ended months of speculation Jan. 22 about how it aims to return to Wall Street's good graces. The move signals an attempt by the sprawling organization to adjust to an era where it's far more difficult to rely on blockbuster drugs to do the financial heavy lifting.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.